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OBJECTIVES The purpose of this study was to determine whether endothelial dysfunction as a consequence
of direct postprandial lipid response might be favorably influenced by angiotensin-converting
enzyme inhibitors or angiotensin AT1 receptor antagonists.
BACKGROUND Postprandial triglyceride-rich lipoproteins cause endothelial dysfunction. Angiotensin-
converting enzyme inhibitors have been shown to improve vascular reactivity. For angiotensin
II type 1 receptor antagonists this effect is as yet uncertain.
METHODS A randomized, double-blind, placebo-controlled crossover study in 30 healthy volunteers,
aged 18 to 33 years, evaluated the effect of quinapril (40 mg daily for two weeks) and losartan
(50 mg daily for two weeks) on basal as well as postprandial endothelial function measured
noninvasively as percentage diameter change in the brachial artery after reactive hyperemia.
Endothelium-independent dilation was measured after nitroglycerine spray sublingual.
RESULTS An acute oral fat load impaired endothelial function. Flow-mediated vasodilation (FMD)
decreased from a median of 6.2% to 4.2% (p , 0.05). There was no significant difference in
preprandial endothelial function after two weeks of treatment with either quinapril or losartan
compared with placebo in these healthy volunteers. Both quinapril (FMD 6.4% to 6.3%) and
losartan (7.1% to 5.4%) prevented endothelial dysfunction induced by an oral fat load,
although the protective effect of quinapril appeared to be more profound. The response to the
endothelium-independent vasodilator nitroglycerine was unaltered throughout the study.
CONCLUSIONS Both losartan and quinapril prevent endothelial dysfunction induced by triglyceride-rich
lipoproteins in healthy volunteers. However, the protective effect of quinapril is more
pronounced. (J Am Coll Cardiol 1999;34:140–5) © 1999 by the American College of
Cardiology
Endothelial dysfunction is a primary event in atherogenesis
and all known cardiovascular risk factors have been associ-
ated with endothelial dysfunction before atherosclerotic
vascular disease manifests itself clinically (1–3). Pivotal to
endothelial dysfunction is a disturbance in the function of
endothelium-derived nitric oxide (NO) (4).
It has been generally accepted that low density lipopro-
tein (LDL) cholesterol is a key factor in atherogenesis.
Currently, evidence is accumulating that triglyceride-rich
remnant particles may also be involved. In vitro,
triglyceride-rich lipoproteins can induce macrophage lipid
loading (5), penetrate arterial tissue and accumulate within
the subendothelial space, consistent with the site of athero-
genesis (6,7). In agreement, triglyceride-rich lipoproteins
(endogenous and postprandial) have been shown to relate to
the rate of progression of coronary artery disease (8,9) as
well as progression of carotid artery intima–media thickness
(10).
Recently, abnormal endothelium-dependent vasomotor
function has been shown to be associated with triglyceride-
rich remnant lipoprotein levels in both the coronary and the
brachial artery (11, 12). This may bear direct consequences
for disorders in which the clearance of triglyceride-rich
lipoproteins is impaired, such as diabetes, familial combined
hyperlipidemia, postmenopausal women and apolipoprotein
E2/E2 genotype (13). In line with the hypothesis that
endothelial function can be used as a surrogate end point for
cardiovascular morbidity, therapeutic modulation of post-
prandial endothelial dysfunction may potentially contribute
to prevention of cardiovascular disease in these patients.
Angiotensin-converting enzyme (ACE) is strategically
positioned on the endothelium to influence the activity of at
least three local vasoactive systems: angiotensin II, bradyki-
nin and NO. Angiotensin-converting enzyme inhibition has
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two major actions: prevention of angiotensin II formation
and prevention of bradykinin breakdown. Angiotensin II is
a potent vasoconstrictor and a strong stimulator of super-
oxide production, for example, by vascular nicotinamide
adenine dinucleotide, reduced form oxidase (14). Super-
oxide reacts with NO at a diffusion-limited rate, thus
constituting a main degradation pathway for NO (15).
Bradykinin is a vasodilator, in part due to direct stimulation
of NO synthase. However, it may also cause release of
endothelium-dependent hypopolarizing factor (16). In line
with these actions, several studies have shown that admin-
istration of ACE inhibitors improves endothelial function,
for example, in subjects with diabetes (17) and patients with
coronary artery disease (18). To what extent angiotensin II
type 1 receptor antagonists affect endothelial function is as
yet unclear. However, if inhibition of the formation of
angiotensin II is important for the improvement of endo-
thelial function observed with ACE inhibition, then a
favorable effect of angiotensin II type 1 receptor antagonists
could be expected.
The objectives of the present study were to test whether
ACE inhibition and angiotensin II type 1 receptor antag-
onism influence endothelial function, assessed as flow-
mediated dilation (FMD), in healthy volunteers and to
evaluate whether postprandial endothelial dysfunction can
be improved by ACE inhibition or angiotensin II type 1
receptor antagonism.
METHODS
Subjects. Thirty healthy volunteers, aged 18 to 33 years,
participated. All individuals were normotensive and had no
history of cardiovascular disease, or family history of pre-
mature vascular disease. All subjects had fasting plasma
triglyceride and cholesterol concentrations below 2.0 mmol/
liter and 6.5 mmol/liter, respectively. The subjects did not
use medication.
The study was approved by the Medical Ethics Commit-
tee of University Hospital Utrecht and written informed
consent was obtained from all participants.
Study design. The effect of two weeks of placebo, quinapril
or losartan therapy on FMD before and after oral fat load
was studied by use of a randomized, double-blind, placebo-
controlled crossover protocol. Subjects were randomized to
receive quinapril 40 mg once daily (Acupril, Parke-Davis),
losartan 50 mg once daily (Cozaar, Merck Sharpe &
Dohme) or a similarly packaged placebo. After two weeks
each subject returned for a study of forearm vascular
function before and 4 h after an oral fat load. Two weeks of
washout followed. After crossover, they were restudied four
weeks later. The same routine was performed for the final
measurement. The subjects refrained from drinking
caffeine-containing beverages, smoking and eating 12 h
before each procedure. At each visit blood samples were
drawn for laboratory determinations of triglycerides, total
cholesterol and high density lipoprotein cholesterol concen-
trations before and 4 h after an oral fat load, which consisted
of 50 g of fat per m2 body surface in the form of whipped
cream (40% fat).
Forearm vascular test. The ultrasound measurements were
performed in the supine position at the elbow of the right
arm using a vessel wall-movement system (Wall Track
System, Pie Medical, Maastricht, The Netherlands), which
consists of an ultrasound imager with a 7.5-MHz linear
array transducer connected to a data acquisition system and
a personal computer. An optimal two-dimensional B-mode
image of the brachial artery was obtained. An M line
perpendicular to the vessel was selected. The ultrasound
system was switched to M mode, after which storage of data
started. The vessel movement detector system repeatedly
registered end-diastolic vessel diameter during a period of
five to six cardiac cycles. This procedure was performed
three times. The measurements were averaged for the
baseline diameter.
By inflation of a blood pressure cuff for 4 min at a
pressure of 100 mm Hg above the systolic blood pressure,
ischemia was applied to the forearm distal to the location of
the transducer. Ultrasonography continued for 3 min after
cuff release with measurements at 30-s intervals. The widest
lumen diameter was taken as a measure for maximal
diameter. After 10 min of rest, allowing the artery to return
to its baseline diameter, sublingual nitroglycerine spray was
administered as an endothelium-independent dilator. Mea-
surements were obtained for another 5 min, at 1-min
intervals.
Flow-mediated dilation and nitroglycerine-induced dila-
tion were expressed as a percentage change relative to
baseline diameter.
Statistical analysis. Group values are expressed as mean 6
SD. Due to failure of the normality test for FMD data,
FMD values are expressed as median (25th to 75th percen-
tile) and statistical tests on ranks were used. Differences in
FMD at baseline between the three treatment periods were
tested with a one-way repeated measures analysis of variance
on ranks. Differences in FMD before and after lipid load
within one treatment session were tested with the Wilcoxon
signed rank test. Differences between changes in FMD
before and after lipid load between the various treatment
sessions were tested with one-way repeated measures anal-
ysis of variance. If variance ratios reached statistical signif-
icance, differences were analyzed with the Student-
Newman-Keuls test for p , 0.05.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
FMD 5 flow-mediated dilation
LDL 5 low density lipoprotein
NO 5 nitric oxide
NTG 5 Nitroglycerin induced dilation
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Lipid changes before and after lipid load and between
treatment groups were tested using paired samples t test
with Bonferroni correction. Correlation testing was per-
formed using linear regression. Differences were considered
significant at p , 0.05.
RESULTS
The general characteristics of the study group are given in
Table 1. Preprandial and postprandial endothelial function
values are shown in Table 2. The baseline arterial diameter
and FMD before fat loading were not significantly different
between placebo, quinapril and losartan treatment. Total
cholesterol, triglyceride and high density lipoprotein cho-
lesterol concentrations did not differ between the three
groups studied, before as well as after fat loading; values are
shown in Table 3. Upon fat loading trygliceride concentra-
tions were significantly increased in all three groups,
whereas the other lipid parameters remained unaltered
(Table 3).
During placebo therapy an oral fat load induced a
significant decrease in FMD (Table 2). There was an
inverse relation between the level of postprandial
trygliceride concentration and FMD after fat load. The
mean change in FMD per mmol increase of triglycerides
was 21.71% (95% confidence interval: 23.35 to 20.61,
p , 0.05).
During losartan treatment postprandial FMD was no
longer significantly different from preprandial FMD (Table
2). Accordingly, the relation between postprandial triglyc-
erides and FMD after fat load was no longer significant.
However, there was still a tendency toward a decrease in
FMD, which was underscored by the observation that the
change in FMD (difference between pre- and postprandial)
was not significantly different during placebo compared with
losartan treatment; values are shown in Figure 1.
During quinapril treatment postprandial FMD was not
significantly different from preprandial FMD (Table 2).
Comparable to losartan, there was no relation between
postprandial triglycerides and FMD after fat load. The
change in postprandial endothelial function compared with
preprandial endothelial function was significantly different
between quinapril and placebo treatment as well as quinapril
and losartan treatment, implying that the ameliorative effect
of ACE inhibition on postprandial endothelial dysfunction
was more profound than the effect of angiotensin II type 1
receptor antagonism. Values are shown in Figure 1.
Responses to the endothelium-independent vasodilator
nitroglycerine were not significantly altered by either an oral
fat tolerance test, or quinapril or losartan therapy (Table 4).
DISCUSSION
In the present study we demonstrate that the impairment of
endothelial function upon acute fat load is prevented by two
weeks therapy with both the angiotensin II type 1 receptor
antagonist losartan and the ACE inhibitor quinapril. The
effect of ACE inhibition on postprandial endothelial dys-
function appeared to be more profound.
Postprandial lipemia and endothelial function. Acute fat
loading induces a consistent reduction in FMD in healthy
volunteers. In the present study we observe a clear correla-
tion between the degree of impairment of FMD and the
levels of postprandial triglycerides, which was abolished
during angiotensin II type 1 receptor antagonist and ACE
inhibition therapy. Whereas most studies have evaluated
relations between endothelium-dependent vasodilation and
LDL cholesterol (19), two recent studies have emphasized
the potential relevance of triglyceride-rich lipoproteins for
endothelial function. Remnant lipoprotein levels were inde-
pendently associated with endothelial dysfunction in epicar-
dial coronary arteries in patients without angiographically
proven vascular disease (11). Also, in patients with familial
combined hyperlipidemia improvement of endothelial func-
tion in the forearm vasculature was significantly correlated
to reduction of intermediate density lipoprotein cholesterol
after lipid-lowering treatment (20). These findings have
been substantiated in vitro, where (oxidized) chylomicron
remnants have been shown to impair endothelium-derived
NO activity in rat aortic vessel rings (21). Mechanistically,
decreased NO bioavailability may be the consequence of
decreased NO formation or increased NO degradation by
oxygen radicals. Postprandial lipemia was recently shown to
be associated with increased free radical generation in vivo
in type II diabetic patients (22). Also, pretreatment with the
radical scavenger vitamin C could eliminate postprandial
endothelial dysfunction (12).
Table 2. Flow-Mediated Dilation Pre- and Postprandial During
Placebo, Quinapril and Losartan Treatment
Placebo Quinapril Losartan
Preprandial 6.2 (3.8–9.9) 6.4 (2.1–8.4) 7.1 (2.7–10.0)
Postprandial 4.2 (1.8–6.3)* 6.3 (4.3–10.1) 5.4 (2.5–9.0)
*p , 0.05 compared with preprandial flow-mediated dilation after placebo treatment.
Values are percentages with 25th to 75th percentile in parentheses.
Table 1. General Characteristics of the Study Group
Participants 30
Age (yr) 23 (3.3)
Male gender (%) 50
Systolic blood pressure (mm Hg) 134 (14.6)
Diastolic blood pressure (mm Hg) 70 (9.4)
Total cholesterol (mmol/liter) 4.8 (0.9)
Triglyceride (mmol/liter) 1.0 (0.4)
Smoking (%) 23
Body mass index (kg/m2) 22.6 (2.7)
Vessel size (mm) 4.3 (0.7)
FMD (%) 6.2 (3.8–9.9)
NTG (%) 14.1 (10.7–16.2)
Values are percentages, means or median with standard deviation or 25th to 75th
percentile in parentheses.
FMD 5 flow-mediated dilation; NTG 5 nitroglycerin-induced dilation.
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Role of the vascular renin–angiotensin system and endo-
thelial function. In the present study neither ACE inhi-
bition nor angiotensin II type 1 receptor antagonism af-
fected endothelial function before lipid load. In a previous
study endothelial function was improved during ACE
inhibition in healthy subjects (23). However, in the latter
study the ACE inhibitor was infused acutely, which may
(partly) account for the differences in observation. Postpran-
dial endothelial dysfunction could be blocked by both
losartan as well as quinapril, whereas endothelium-
independent responses were unaltered during the various
treatments. This finding further corroborates data suggest-
ing a protective effect of ACE inhibition against lipid-
associated endothelial dysfunction.
The toxic effect of ox-LDL on endothelial function in
aortic rings could be abolished by ACE inhibition (24),
whereas ACE inhibition also slowed progression of athero-
sclerosis in cholesterol-fed rabbits (25). Accordingly, the
ameliorative effect of ACE inhibition on endothelial func-
tion was larger with higher cholesterol levels (26).
Angiotensin-converting enzyme inhibition also retarded
progression of coronary atherosclerosis in subjects with
LDL cholesterol levels above 130 mg/dl (27). This en-
hanced effectivity of ACE inhibition during higher choles-
terol levels, combined with the observations of the present
study, suggest that the vascular renin–angiotensin system
may be somehow involved in the mechanism of lipid-
induced endothelial dysfunction.
Table 3. Lipid Values Before and After Oral Fat Load During Placebo, Quinapril and Losartan Treatment
Placebo Quinapril Losartan
Preprandial Postprandial Preprandial Postprandial Preprandial Postprandial
Total cholesterol (mmol/liter) 4.2 (0.7) 4.3 (0.8) 4.1 (0.5) 4.3 (0.6) 4.1 (0.8) 4.1 (0.8)
HDL cholesterol (mmol/liter) 1.1 (0.2) 1.1 (0.2) 1.2 (0.3) 1.2 (0.3) 1.2 (0.2) 1.2 (0.3)
Triglyceride (mmol/liter) 1.2 (0.5) 2.1 (1.1)* 1.1 (0.4) 1.8 (0.6)* 1.1 (0.4) 2.1 (0.9)*
*p , 0.05 compared with preprandial values. Values are means with standard deviations in parentheses.
HDL 5 high density lipoprotein.
Figure 1. Change in postprandial flow-mediated dilation (FMD) compared with preprandial FMD during placebo, quinapril and losartan
treatment. The bars represent means with standard errors. Diagonally striped bars 5 placebo; solid bars 5 losartan; vertically striped
bars 5 quinapril. #p , 0.05, placebo compared with quinapril treatment. *p , 0.05, losartan compared with quinapril treatment.
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Potential mechanism. Theoretically, two mechanisms can
be involved. Triglyceride-rich lipoproteins may, in analogy
to LDL, induce increased oxygen radical production by a
renin–angiotensin modifiable pathway. Membrane oxidases,
which have been implicated as important superoxide-
producing enzymes in the vasculature, are (in part) regulated
by angiotensin II (14). Hence, decreased angiotensin II
formation may result in down-regulation of the expression
of membrane oxidases, resulting in decreased lipid-induced
superoxide production. The ensuing increase in NO bio-
availability can arise either due to decreased destruction of
NO by decreased superoxide itself or due to decreased
formation of, for example, oxidatively modified chylomi-
crons, which may interfere with NO production and/or NO
bioavailability. In addition, bradykinin-mediated stimula-
tion of endothelial function may also be involved, which is
supported by the significant difference in effect between
quinapril and losartan in preventing the change in postpran-
dial endothelial function. In agreement, the protective effect
of ACE inhibition against the toxicity of ox-LDL in rat
aortic rings was also shown to be bradykinin dependent
(23). Interestingly, preprandial endothelial dysfunction was
unaffected by ACE inhibition, which may imply that the
bradykinin pathway is of particular importance during
dyslipidemia. In this respect, bradykinin-stimulated endo-
thelial function has been shown to be preserved in hyper-
cholesterolemic patients, whereas other agonist-stimulated
endothelial function, that is, acetylcholine, serotonin and
alpha2 receptor stimulation, is impaired (28). Alternatively,
differences in pharmacokinetics, such as binding and tissue
penetration, may have contributed to the observed differ-
ences between quinapril and losartan. It is less likely that the
difference in effect is the result of the dosage of losartan used
in this study, since losartan reaches a plateau in the
dose–response curve after 50 mg (29).
The exact nature of the interaction between lipid-induced
endothelial dysfunction and the renin–angiotensin system
deserves further research. Nevertheless, the observation that
postprandial endothelial dysfunction can be improved by
blockade of the renin–angiotensin system provides a ratio-
nale for ACE inhibition and/or angiotensin type 1 receptor
antagonist therapy in patients with impaired remnant par-
ticle clearance such as diabetes and familial combined
hyperlipidemia.
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